Insilicos Awarded Grant Applying GPU Computing to Epistasis
Seattle, 2 October 2010 - Insilicos today announced the company has received a grant applying GPU computing to the genomic phenomenon called epistasis. The grant is from the National Human Genome Research Institute, part of the National Institutes of Health. This is the third research grant Insilicos has received in 2010.
Epistasis occurs when the effects of one gene are modified by one or more other genes. GPU computing uses graphics accelerator cards as parallel computation engines for a "desktop supercomputer."
"This research requires extensive computation," said Insilicos researcher Mark Seligman, principal investigator on the grant. "Our goal is to use new statistical methods with GPU computing to make such research practical on a desktop computer."
The research will compare data on eQTLs (expression quantitative trait loci, SNPs which are associated with the expression of a gene) to GWAS (genome-wide association studies) data. GPU computing will quickly perform the necessary computations on an inexpensive desktop computer.
Insilicos LLC is a biomarker discovery and diagnostic development company, concentrating on cardiovascular disease.
For more information, visit the Insilicos web site www.insilicos.com or contact Insilicos at info@insilicos.com. 'Insilicos' 'PreClue," and 'Life Science Software' are trademarks of Insilicos LLC.
